Mode
Text Size
Log in / Sign up
N/A N=143 Randomized Double-blind Treatment

Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella Area

Cosmetic Techniques

Enrolled (actual)
143
Serious AEs
0.0%
Results posted
Jan 2025
Primary outcome: Primary: the Change in Dynamic Strain in the Glabella Area After Injection Over Time — 6.4; 10.9; 6.6; 8.9 percent difference of neutral+dyanamic

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Onabotulinumtoxina for Injection (Drug); Abobotulinumtoxina for Injection (Drug); IncobotulinumtoxinA for Injection (Drug); PrabotulinumtoxinA for Injection (Drug)
Age
Adult, Older Adult · 30+ yrs
Sex
Female
Sponsor
University of Pennsylvania
Primary completion
Jun 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
the Change in Dynamic Strain in the Glabella Area After Injection Over Time
6.4; 10.9; 6.6; 8.9; 8.6; 10.6
SECONDARY
Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime
-0.0870; -0.013; 0.049; -0.095; 0.033; -0.018 0.13519

Summary

The purpose of the study is to use 3D imaging to evaluate the effects of four FDA approved neuromodulators on facial lines, wrinkles and animation. Participation is available to women who have never had a cosmetic procedure above the malar region nor a treatment with a neuromodulator within 12 months. All subjects will undergo 3D imaging using the VECTRA M3 (Canfield Scientific, Inc, Fairfield, NJ) prior to treatment with a neuromodulator in order to determine their baseline dimensions. Imaging will be repeated post injection to determine change over time.

Eligibility Criteria

Inclusion Criteria

  • Female
  • 30-65 years of age
  • Interested in glabellar injections to reduce rhytids and facial strain
  • Participants must sign the informed consent form

Exclusion Criteria

  • Females under 30 or above 65 years of age
  • Males
  • Those who have received glabellar injections for rhytids <12 months
  • Underwent cosmetic surgical procedure above the malar region
  • Those with a condition that affects facial expression, such as prior stroke
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05167864). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search